Non-vision adverse events with vigabatrin therapy.

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Neurology

Background:

• Vigabatrin is an established antiepileptic drug (AED) for refractory complex partial seizures (rCPS) and infantile spasms (IS).
• Previous clinical trials indicated a generally favorable safety profile comparable to other AEDs, with common side effects being CNS-related.

Purpose of the Study:

• To review the safety and tolerability profile of vigabatrin, focusing on adverse events and specific concerns like intramyelinic edema (IME) and MRI abnormalities.
• To inform the risk-benefit assessment for vigabatrin therapy in epilepsy management.

Main Methods:

• Review of clinical trial data, including adverse event reporting and neuropsychological testing.
• Analysis of findings related to intramyelinic edema (IME) in animal models and humans.
• Evaluation of magnetic resonance imaging (MRI) and evoked potential (EP) data in patients receiving vigabatrin.

Main Results:

• Common adverse events include drowsiness, dizziness, fatigue, sedation, somnolence, and irritability.
• Vigabatrin showed minimal impact on cognitive function, mood, or behavior in adults with rCPS.
• Increased incidence of depression and psychosis observed compared to placebo.
• Intramyelinic edema (IME) initially raised safety concerns but was not detected in later assessments in older patients.
• MRI abnormalities (increased T2 intensity, restricted diffusion) were identified in infants with IS, often resolving with treatment changes.

Conclusions:

• Vigabatrin is an effective AED for specific epilepsy types, but its use requires careful consideration of potential risks.
• Balancing seizure control benefits against risks such as CNS effects, psychiatric events, and MRI abnormalities is crucial.
• Monitoring for and managing adverse events, particularly in infants, is essential for safe vigabatrin therapy.